Please describe your clinical practice. How many patients with PPD do you see on a yearly basis? What is the standard of care, and how well do patients respond to it?

How often and well do antidepressants work in PPD? What is the most important criteria in selecting first-line anti-depressant medication such as sertraline SSRI?

Brexanolone reported Breastmilk level results, where 95% of patients had milk allopregnanolone levels <10 mcg/L at 36 hours after the end of the infusion. The predicted weight-adjusted percent of maternal dosage was 1.3% and that the amount in milk was 1% to 2% of the weight-adjusted maternal dosage. Could you discuss on the limitations of this data and what your thoughts are on the subject?

How often is non-pharmacotherapy/ hormone therapy the more indicated approach and in which circumstances?

Could you draw some parallels to the other allopregnanolone analogs under evaluation for use in the treatment of PPD such as ganaxolone?

How likely are patients to opt out of the therapy considering its approval under the Risk Evaluation and Mitigation Strategy (REMS) program, where the therapy consists of a 60-hour infusion process and the patient requires constant supervision?

How could potential side-effects such as flushing and loss of consciousness, suicidal thoughts or behavior influence the therapy’s uptake in the future. Do you see risks there?

How likely would you be to switch patients to zuranolone?